Tovorafenib Clinical Trials
6 recruitingDrug
Phase 24Phase 11Early Phase 11Phase 31
Showing 1–6 of 6 trials
Recruiting
Phase 2
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Recurrent Langerhans Cell HistiocytosisRefractory Langerhans Cell Histiocytosis
National Cancer Institute (NCI)48 enrolled117 locationsNCT05828069
Recruiting
Phase 1Phase 2
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Hairy Cell LeukemiaRecurrent Hairy Cell LeukemiaRefractory Hairy Cell Leukemia
National Cancer Institute (NCI)84 enrolled4 locationsNCT06965114
Recruiting
Phase 2
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
CraniopharyngiomaCraniopharyngioma, ChildRecurrent Craniopharyngioma
Sabine Mueller, MD, PhD57 enrolled20 locationsNCT05465174
Recruiting
Phase 3
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Low-grade GliomaRapidly Accelerated Fibrosarcoma (RAF) Altered GliomaPediatric Low-grade Glioma
Day One Biopharmaceuticals, Inc.400 enrolled138 locationsNCT05566795
Recruiting
Early Phase 1
Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
Low-grade Glioma
Daniel Morgenstern57 enrolled1 locationNCT06381570
Recruiting
Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Advanced Solid TumorLow-grade Glioma
Day One Biopharmaceuticals, Inc.141 enrolled35 locationsNCT04775485